Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.

Treszl A, Schally AV, Seitz S, Szalontay L, Rick FG, Szepeshazi K, Halmos G.

Peptides. 2009 Sep;30(9):1643-50. doi: 10.1016/j.peptides.2009.06.007. Epub 2009 Jun 12.

PMID:
19524629
2.

AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.

Engel J, Emons G, Pinski J, Schally AV.

Expert Opin Investig Drugs. 2012 Jun;21(6):891-9. doi: 10.1517/13543784.2012.685128. Review.

PMID:
22577891
3.
4.

Somatostatin and the lung.

O'Byrne KJ, Carney DN.

Lung Cancer. 1993 Dec;10(3-4):151-72. Review.

PMID:
7915618
5.

P2 receptors and cancer.

White N, Burnstock G.

Trends Pharmacol Sci. 2006 Apr;27(4):211-7. Epub 2006 Mar 13. Review.

PMID:
16530853
6.

Chemotherapy targeted to cancers through tumoral hormone receptors.

Schally AV, Nagy A.

Trends Endocrinol Metab. 2004 Sep;15(7):300-10. Review.

PMID:
15350601
7.

Pre-clinical experience with Re-188-RC-160, a radiolabeled somatostatin analog for use in peptide-targeted radiotherapy.

Zamora PO, Bender H, Gulhke S, Marek MJ, Knapp FF Jr, Rhodes BA, Biersack HJ.

Anticancer Res. 1997 May-Jun;17(3B):1803-8. Review.

PMID:
9179237
8.

New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.

Crawford J.

J Natl Compr Canc Netw. 2003 Jan;1 Suppl 1:S78-86. Review.

PMID:
19795580
10.

Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.

Nagy A, Schally AV.

Biol Reprod. 2005 Nov;73(5):851-9. Epub 2005 Jul 20. Review.

PMID:
16033997
11.

[Advances in the study of small peptides in targeted drug delivery system].

Sun Y, Wang C.

Yao Xue Xue Bao. 2008 Oct;43(10):992-6. Review. Chinese.

PMID:
19127861
12.

Pemetrexed for the treatment of non-small-cell lung cancer.

Manegold C, Schmid-Bindert G, Pilz LR.

Expert Rev Anticancer Ther. 2009 Sep;9(9):1195-209. doi: 10.1586/era.09.97. Review.

PMID:
19761423
13.

TT-232: a somatostatin structural derivative as a potent antitumor drug candidate.

Szende B, Kéri G.

Anticancer Drugs. 2003 Sep;14(8):585-8. Review.

PMID:
14501379
14.

Epidermal growth factor receptor as a target in cancer therapy.

Kim ES.

J Natl Compr Canc Netw. 2003 Jan;1 Suppl 1:S87-95. Review.

PMID:
19795581
15.

Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors.

Kvols LK, Woltering EA.

Anticancer Drugs. 2006 Jul;17(6):601-8. Review.

PMID:
16917205
16.

New approaches to the therapy of various tumors based on peptide analogues.

Schally AV.

Horm Metab Res. 2008 May;40(5):315-22. doi: 10.1055/s-2008-1073142. Review.

PMID:
18491250
17.

Antitumor effects of somatostatin.

Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini C.

Mol Cell Endocrinol. 2008 May 14;286(1-2):230-7. doi: 10.1016/j.mce.2008.02.002. Epub 2008 Feb 13. Review.

PMID:
18359151
18.

Vitamin B12-mediated transport: a potential tool for tumor targeting of antineoplastic drugs and imaging agents.

Gupta Y, Kohli DV, Jain SK.

Crit Rev Ther Drug Carrier Syst. 2008;25(4):347-79. Review.

PMID:
18540842
19.

Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.

Oberg K.

Expert Rev Anticancer Ther. 2009 May;9(5):557-66. doi: 10.1586/era.09.26. Review.

PMID:
19445573
20.

[Recent advances in the study of structure modification of somatostatin].

Gong X, Han X, Wang DX.

Yao Xue Xue Bao. 2006 Nov;41(11):1027-33. Review. Chinese. No abstract available.

PMID:
17262942

Supplemental Content

Support Center